Free public records show Hangzhou Endonom Medtech Co., Ltd. in 2 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Hangzhou Endonom Medtech Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
6 active studies led by Hangzhou Endonom Medtech Co., Ltd., of 17 in all
Source: ClinicalTrials.gov, Studies with Hangzhou Endonom Medtech Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies Hangzhou Endonom Medtech Co., Ltd. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Hangzhou Endonom Medtech Co., Ltd. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Hangzhou Endonom Medtech Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Hangzhou Endonom Medtech Co., Ltd. is in.
Stories on the topics Hangzhou Endonom Medtech Co., Ltd. works in.
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
More than half of deaths in low- and middle-income countries come from conditions emergency care could treat…
Read
57 million people live with dementia. In May 2025 the US FDA cleared the first blood test used to help…
ReadSearch all reports for Hangzhou Endonom Medtech Co., Ltd. All companies